Terms: = Prostate cancer AND STK11, LKB1, 6794, ENSG00000118046, Q15831, PJS AND Treatment
20 results:
1. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
2. Auraptene Enhances AMP-Activated Protein Kinase Phosphorylation and Thereby Inhibits the Proliferation, Migration and Expression of Androgen Receptors and prostate-Specific Antigens in prostate cancer Cells.
Akasaka Y; Hasei S; Ohata Y; Kanna M; Nakatsu Y; Sakoda H; Fujishiro M; Kushiyama A; Ono H; Matsubara A; Hinata N; Asano T; Yamamotoya T
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958994
[No Abstract] [Full Text] [Related]
3. STAT3/lkb1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Pencik J; Philippe C; Schlederer M; Atas E; Pecoraro M; Grund-Gröschke S; Li WJ; Tracz A; Heidegger I; Lagger S; Trachtová K; Oberhuber M; Heitzer E; Aksoy O; Neubauer HA; Wingelhofer B; Orlova A; Witzeneder N; Dillinger T; Redl E; Greiner G; D'Andrea D; Östman JR; Tangermann S; Hermanova I; Schäfer G; Sternberg F; Pohl EE; Sternberg C; Varady A; Horvath J; Stoiber D; Malcolm TI; Turner SD; Parkes EE; Hantusch B; Egger G; Rose-John S; Poli V; Jain S; Armstrong CWD; Hoermann G; Goffin V; Aberger F; Moriggl R; Carracedo A; McKinney C; Kennedy RD; Klocker H; Speicher MR; Tang DG; Moazzami AA; Heery DM; Hacker M; Kenner L
Mol Cancer; 2023 Aug; 22(1):133. PubMed ID: 37573301
[TBL] [Abstract] [Full Text] [Related]
4. Mutations in epigenetic regulator
Zhu S; Xu N; Liang J; Zhao F; Wang Z; Ni Y; Dai J; Zhao J; Zhang X; Chen J; Sun G; Shen P; Zeng H
Oncol Res; 2023; 31(4):605-614. PubMed ID: 37415738
[TBL] [Abstract] [Full Text] [Related]
5. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
6. Capilliposide B inhibits the migration of prostate cancer by inducing autophagy through the ROS/AMPK/mTOR pathway.
Wang L; Han H; Feng Y; Ma J; Han Z; Li R; Zhu W; Li S; Tian J; Zhang L
Phytother Res; 2023 Jul; 37(7):2902-2914. PubMed ID: 36867511
[TBL] [Abstract] [Full Text] [Related]
7. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
[TBL] [Abstract] [Full Text] [Related]
8. Sequential monoscopic image-guided motion compensation in tomotherapy stereotactic body radiotherapy (SBRT) for prostate cancer.
Lu L; Chao E; Zhu T; Wang AZ; Lian J
Med Phys; 2023 Jan; 50(1):518-528. PubMed ID: 36397645
[TBL] [Abstract] [Full Text] [Related]
9. Current Status and Application of Metformin for prostate cancer: A Comprehensive Review.
Ahn HK; Lee YH; Koo KC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198356
[TBL] [Abstract] [Full Text] [Related]
10. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
11. Concurrent regulation of lkb1 and CaMKK2 in the activation of AMPK in castrate-resistant prostate cancer by a well-defined polyherbal mixture with anticancer properties.
MacDonald AF; Bettaieb A; Donohoe DR; Alani DS; Han A; Zhao Y; Whelan J
BMC Complement Altern Med; 2018 Jun; 18(1):188. PubMed ID: 29914450
[TBL] [Abstract] [Full Text] [Related]
12. CO suppresses prostate cancer cell growth by directly targeting lkb1/AMPK/mTOR pathway in vitro and in vivo.
Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
[TBL] [Abstract] [Full Text] [Related]
13. Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Biernacka KM; Persad RA; Bahl A; Gillatt D; Holly JM; Perks CM
Endocr Relat Cancer; 2017 Jan; 24(1):17-30. PubMed ID: 27754854
[TBL] [Abstract] [Full Text] [Related]
14. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Pilon D; Queener M; Lefebvre P; Ellis LA
J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
[TBL] [Abstract] [Full Text] [Related]
15. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
[TBL] [Abstract] [Full Text] [Related]
16. A unique amidoanthraquinone derivative displays antiproliferative activity against human hormone-refractory metastatic prostate cancers through activation of lkb1-AMPK-mTOR signaling pathway.
Hsu JL; Liu SP; Lee CC; Hsu LC; Ho YF; Huang HS; Guh JH
Naunyn Schmiedebergs Arch Pharmacol; 2014 Oct; 387(10):979-90. PubMed ID: 25005758
[TBL] [Abstract] [Full Text] [Related]
17. Metformin and cancer.
Vallianou NG; Evangelopoulos A; Kazazis C
Rev Diabet Stud; 2013; 10(4):228-35. PubMed ID: 24841876
[TBL] [Abstract] [Full Text] [Related]
18. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract] [Full Text] [Related]
19. Peutz-Jeghers syndrome: a study of long-term surgical morbidity and causes of mortality.
You YN; Wolff BG; Boardman LA; Riegert-Johnson DL; Qin R
Fam Cancer; 2010 Dec; 9(4):609-16. PubMed ID: 20571886
[TBL] [Abstract] [Full Text] [Related]
20. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells.
Zhou J; Huang W; Tao R; Ibaragi S; Lan F; Ido Y; Wu X; Alekseyev YO; Lenburg ME; Hu GF; Luo Z
Oncogene; 2009 May; 28(18):1993-2002. PubMed ID: 19347029
[TBL] [Abstract] [Full Text] [Related]
